Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18)

Int J Hematol. 2010 Nov;92(4):659-63. doi: 10.1007/s12185-010-0704-8. Epub 2010 Oct 26.

Abstract

Histiocytic sarcoma (HS) is a rare but aggressive malignant neoplasm of histiocytic lineage with a poor prognosis. Immunohistochemically, the neoplastic cells are positive for CD163, CD68, and lysozyme, and negative for B and T cell markers. However, molecular studies on the origin of the neoplastic cells remain inconclusive. A 54-year-old woman was admitted to our hospital because of painful swelling of the left knee. Examination revealed generalized lymphadenopathy and splenomegaly. HS was diagnosed according to morphologic and immunohistochemical features observed on biopsy of the left inguinal lymph node. The tumor demonstrated a clonal immunoglobulin heavy chain gene rearrangement and a clonal cytogenetic abnormality including t(14;18) which was confirmed by fluorescence in situ hybridization analysis showing the IgH/BCL2 fusion gene. The neoplastic cells were negative for PAX5, a B cell associated transcription factor, and positive for CEBPβ, a transcription factor mediating macrophage and myeloid differentiation. Positron emission tomography showed disseminated areas of increased 18F-fluorodeoxyglucose uptake in multiple lymph nodes, the liver, spleen, both lungs, both kidneys, and many bony sites. The patient received localized irradiation therapy followed by chemotherapy, she failed to respond and died of the disease progression. The case findings suggest lineage promiscuity or plasticity related to the pathogenesis of HS.

Publication types

  • Case Reports

MeSH terms

  • Chromosomes, Human, Pair 14 / genetics*
  • Chromosomes, Human, Pair 18 / genetics*
  • Fatal Outcome
  • Female
  • Gene Rearrangement*
  • Genes, Immunoglobulin Heavy Chain*
  • Histiocytic Sarcoma / drug therapy
  • Histiocytic Sarcoma / genetics*
  • Histiocytic Sarcoma / pathology
  • Humans
  • Middle Aged
  • Translocation, Genetic*